Question special

Coming over DAPA-HF trial, we noticed that not only black patients represented less than 5% of all the patients being tested, but also the primary composite outcome occurred in 26 of those patients receiving Dapagliflozin compared to 32 in the arm receiving placebo with no significant difference in the HR 0.62, 95% CI(0.37-1.04). The same findings were noted before in the black patients on previous trials testing SGLT2i therapy whether CANVAS trial or EMPA-REG outcome. Given that, do you think the race will be a factor determining the eligibility of HFrEF patients to receive SGLT2i therapy?